| Stem definition | Drug id | CAS RN |
|---|---|---|
| tricyclic compounds | 951 | 113-53-1 |
| Dose | Unit | Route |
|---|---|---|
| 0.15 | g | O |
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 500 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 5 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 6.46 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 30 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1962 | YEAR INTRODUCED |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Acute kidney injury | 49.02 | 30.93 | 44 | 1446 | 263371 | 63224161 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Head discomfort | 239.20 | 73.40 | 43 | 495 | 4073 | 34952320 |
| Migraine | 177.21 | 73.40 | 43 | 495 | 17435 | 34938958 |
| Neck pain | 161.33 | 73.40 | 43 | 495 | 25306 | 34931087 |
| Back pain | 95.21 | 73.40 | 43 | 495 | 121746 | 34834647 |
| Headache | 74.87 | 73.40 | 43 | 495 | 200592 | 34755801 |
| Pain | 74.07 | 73.40 | 43 | 495 | 204632 | 34751761 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Head discomfort | 156.88 | 30.24 | 42 | 2025 | 14460 | 79727861 |
| Neck pain | 89.18 | 30.24 | 42 | 2025 | 75375 | 79666946 |
| Migraine | 80.32 | 30.24 | 41 | 2026 | 87452 | 79654869 |
| Back pain | 54.45 | 30.24 | 52 | 2015 | 304128 | 79438193 |
| Headache | 33.26 | 30.24 | 60 | 2007 | 653712 | 79088609 |
| Anticholinergic syndrome | 32.21 | 30.24 | 9 | 2058 | 3602 | 79738719 |
None
| Source | Code | Description |
|---|---|---|
| ATC | N06AA16 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Non-selective monoamine reuptake inhibitors |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D018759 | Adrenergic Uptake Inhibitors |
| MeSH PA | D000928 | Antidepressive Agents |
| MeSH PA | D000929 | Antidepressive Agents, Tricyclic |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D049990 | Membrane Transport Modulators |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D014179 | Neurotransmitter Uptake Inhibitors |
| MeSH PA | D011619 | Psychotropic Drugs |
| CHEBI has role | CHEBI:35469 | antidepressants |
| CHEBI has role | CHEBI:149553 | anticoronaviral drug |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Major depressive disorder | indication | 370143000 |
None
None
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.66 | Basic |
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium-dependent serotonin transporter | Transporter | INHIBITOR | Kd | 8.07 | WOMBAT-PK | IUPHAR | |||
| Sodium-dependent noradrenaline transporter | Transporter | INHIBITOR | Kd | 7.34 | WOMBAT-PK | IUPHAR | |||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.59 | WOMBAT-PK | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 6.38 | WOMBAT-PK | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 7.92 | WOMBAT-PK | |||||
| Histamine H1 receptor | GPCR | Ki | 8.70 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 7.74 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 6.96 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 7.42 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 7.22 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 7.04 | WOMBAT-PK | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 5.28 | PDSP |
| ID | Source |
|---|---|
| N0000167275 | NUI |
| D01546 | KEGG_DRUG |
| C0013065 | UMLSCUI |
| CHEBI:36798 | CHEBI |
| CHEMBL1492500 | ChEMBL_ID |
| DB09167 | DRUGBANK_ID |
| CHEMBL108947 | ChEMBL_ID |
| 5284550 | PUBCHEM_CID |
| 7549 | IUPHAR_LIGAND_ID |
| 897-15-4 | SECONDARY_CAS_RN |
| 142133 | RXNORM |
| 003960 | NDDF |
| 003961 | NDDF |
| 349856007 | SNOMEDCT_US |
| 396037001 | SNOMEDCT_US |
| 414047005 | SNOMEDCT_US |
| D004308 | MESH_DESCRIPTOR_UI |
| CHEMBL1711280 | ChEMBL_ID |
| 1790 | INN_ID |
| W13O82Z7HL | UNII |
None